Drug intelligence / Profile preview

vitamin D3 + telaprevir + peginterferon alfa-2a + ribavirin

Development stage: Discontinued
Lead developer: Timothy Morgan, MD
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
Administration: Oral, Subcutaneous

Overview

This combination therapy was evaluated in a pilot clinical trial (NCT01890772) led by Dr. Timothy Morgan for the treatment of treatment-naive veterans with genotype 1 chronic hepatitis C. The regimen consists of vitamin D3 (cholecalciferol) added to the standard-of-care triple therapy at the time: telaprevir (an NS3/4A protease inhibitor), peginterferon alfa-2a (an immune modulator), and ribavirin (a nucleoside analog). Vitamin D3 was administered at 5,000 IU daily during a lead-in phase and 15,000 IU weekly during the 12-week treatment phase. The study aimed to determine if vitamin D supplementation could enhance the virologic response and safety profile of the triple therapy by modulating the host immune response and potentially improving viral clearance.

Other names: Vitamin D3 add-on to telaprevir triple therapycholecalciferol + telaprevir + peginterferon alfa-2a + ribavirin

Targets

IMPDH (Inosine-5'-monophosphate dehydrogenase 1)EIF4E (Eukaryotic translation initiation factor 4E)NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)IFNAR (Immune system modulation via type I interferon receptor)VDR (Vitamin D receptor)

Beyond the preview

Go deeper on vitamin D3 + telaprevir + peginterferon alfa-2a + ribavirin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on vitamin D3 + telaprevir + peginterferon alfa-2a + ribavirin.

Explore the full profile